New CAR T-Cell therapy offers hope for Hard-to-Treat lymphoma
NCT ID NCT07319676
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 16 times
Summary
This study tests a personalized cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. Participants receive their own immune cells, modified to target cancer cells. The goal is to find the best dose and see if it safely shrinks tumors. About 30 people aged 10 to 80 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore, 119228, Singapore
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.